GLP-1s

A recap of new GLP-1 research to help you make sense of the new information seeming to hit the news (and your inbox) almost daily

Experts weigh in on the results of a new survey on GLP-1 trends from 300 PCPs, endocrinologists and obesity-certified specialists.

New survey of 300 PCPs, endocrinologists and obesity-certified specialists explores what’s really happening between the patients asking for weight loss drugs and the physicians supporting them.

Insights for building a GLP-1 strategy and optimizing for cost and member experience.

With new anti-obesity meds in the pipeline, including oral GLP-1s, and healthcare costs rising exponentially—what happens next?

A first of its kind research study from Virta Health shows sustained weight loss after deprescribing GLP-1s among a real world population.

Get the results of a new survey of 60 senior health plan leaders to understand how the GLP-1 cost crisis is evolving and how they are handling it.

The first known study to demonstrate sustained health improvements after GLP-1 deprescription.

60 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders weigh in on the growing GLP-1 cost crisis

Whether your organization has felt the tidal wave of GLP-1 claims yet or not - it's coming. Learn about a new set of options to navigate this spike.

GLP-1 drugs are hitting the market with new indications but are rising utilization and prices widening health disparities?

A new survey of 80 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders shines a light on the growing GLP-1 cost crisis